신라젠

215600KOSDAQ자연과학 및 공학 연구개발업

54.0 / 100

Reference Date: 2026-06-10

Financial Score22.5 / 40

News Sentiment17.5 / 25

Momentum4.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but Operating Profit is on a declining trend. Plunged 24.8% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Shinara Gen is a biotech venture company established in 2006, focusing on developing anti-cancer drugs. The company specializes in oncolytic virus therapies, mitotic checkpoint inhibitors, and generic pharmaceuticals. Its oncolytic viruses selectively target cancer cells and are being studied in combination therapies with immune checkpoint inhibitors.

Number of Employees

56people

Average Salary

82.0M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 62.704.0Point

PBR

3.18Industry Average 3.244.0Point

In line with industry avg

ROE

-20.00Industry Average -32.093.5Point

Below industry avg

Debt Ratio

1.50Industry Average 7.318.0Point

Half of industry avg (excellent)

Trend 2023~20253.0 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲67.3% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼10.5% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -26.0% (improving, 3yr)

Detailed News Sentiment

9 totalPositive 6Neutral 2Negative 1Average Sentiment Score 70

Positive
신라젠·신신제약, 수액제 공동 판매…"성장 도모"
신라젠과 신신제약의 수액제 공동 판매 협력으로 양사의 성장 기회 확대.
Positive
신라젠, 신신제약과 전문의약품 수액제 공동판매 계약 체결
신라젠과 신신제약의 수액제 공동판매 계약 체결로 신라젠의 판매 네트워크 확장 및 시장 점유율 증가 기대.
Positive
신라젠 BAL0891 임상연구 초기 데이터 美임상종양학회서 공개
신라젠의 BAL0891 임상 초기 데이터 공개로 항암제 안전성과 적정 용량 확인, 일부 디자인에서의 효능 입증으로 긍정적 시장 반응 예상.

Detailed Momentum

52-week position1.0Point

Near 52w low (0%, downtrend)

Current 2,530Won52-week high 4,97552-week low 2,530

1-month return0.0Point

1m -24.81% (strong drop)

Volume trend3.0Point

Volume flat

Detailed Disclosure

1 totalPositive 0Neutral 1Negative 0

Neutral분기보고서 (2026.03)2026-05-15